A dose escalation study of adipose-derived human mesenchymal stem cell (MSC) therapy was studied in 21 subjects. This dose escalation study confirmed no significant cellular toxicity, but it showed improvement in renal oxygenation and glomerular filtration rate. No significant renal toxicity from cell therapy was shown. A reduction in inflammatory markers including tumor necrosis factor-α, interferon-γ, and neutrophil gelatinase-associated lipocalin was noted in subjects receiving MSC therapy. This study provides short-term safety and renal efficacy for MSC therapy and paves the way forward for future MSC-based interventions in renovascular disease.

在21位受试者中研究了脂肪来源的人间充质干细胞（MSC）治疗的剂量递增研究。这项剂量递增研究证实没有明显的细胞毒性，但显示出肾脏氧合作用和肾小球滤过率的改善。没有显示出细胞疗法对肾脏有明显的毒性作用。在接受MSC治疗的受试者中，包括肿瘤坏死因子-α，干扰素-γ和与中性白细胞明胶酶相关的脂钙素的炎症标记物减少。这项研究为MSC治疗提供了短期安全性和肾脏功效，为将来基于MSC的肾血管疾病干预铺平了道路。